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Introduction: Allergic bronchopulmonary aspergillosis (ABPA) is a complex disease,
triggered by a hypersensitivity reaction to the allergens of Aspergillus fumigatus, a
fungus that opportunistically colonizes the lungs of patients with asthma. The diagnosis of
ABPA is difficult. A major problem is the lack of standardized allergens used in the
determination of specific IgE, but the use of recombinant allergens has been proposed to
overcome this. The aim of the present study is to evaluate whether serological tests for IgE
specific to recombinant allergens of A. fumigatus (rAsp) can aid in the detection of
sensitization to this fungus and in the diagnosis of ABPA.
Methods: This was an observational, cross-sectional study. The diagnosis of ABPA, using
classical criteria, was searched in 65 asthmatics patients with immediate cutaneous
reactivity to A. fumigatus. After that, serum titers of IgE against rAsp f 1, rAsp f 2, rAsp f 3,
rAsp f 4 and rAsp f 6 were determined. In order to compare the differences between
patients with confirmed and excluded diagnosis of ABPA, the two-tailed Fisher’s exact test
was used.
Results: Although 19 of 65 patients had IgE against at least one recombinant, the disease
was diagnosed in only six patients by classical criteria. One of them had IgE against all
recombinant allergens tested and another one had antibody against Asp f 3.
Discussion: The determination of serum IgE against recombinant A. fumigatus allergens in
this group was not helpful to make the diagnosis of ABPA, neither to detect sensitization to
fungus.
& 2007 Published by Elsevier Ltd.Published by Elsevier Ltd.
0320562; fax: +5511 30713189.
.com.br (P. Giavina-Bianchi).
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Allergic bronchopulmonary aspergillosis (ABPA) is a complex
disease, triggered by a hypersensitivity reaction to the
allergens of Aspergillus fumigatus (Asp f).1 The clinical
evolution of the disease consists of periods of remission and
exacerbation, and may include the appearance of central
bronchiectasis and progress to terminal stages with the
presence of pulmonary fibrosis.2 The disease may be divided
into two categories: ABPA-S (serological) that is the initial
phase of the disease, when no bronchiectasis is observable
by high-resolution tomography but other serological criteria
of the disease are present, and ABPA-CB (central bronch-
iectasis), when bronchiectasis occurs.3
In Brazil, a study carried out in Rio de Janeiro in 1997
found 20% prevalence of ABPA among asthmatic patients
sensitive to the fungus A. fumigatus.4
A form of diagnosis based on clinical, laboratory,
radiological, and immunological aspects should be sought,
since the early recognition and treatment of ABPA can
prevent the progression of the disease to pulmonary
fibrosis. The clinical criteria most widely used are those
proposed by Rosenberg and coworkers,5 modified by Green-
berger and Patterson.6 The criteria are non specific for
ABPA and it is very difficult for all of them to be present
at once, since, during the natural evolution of the disease
and during treatment with anti-inflammatory drugs,
there are fluctuations in the levels of antibodies and in
the presence of eosinophilia and pulmonary infiltrates. Years
are often necessary before the diagnosis is confirmed, by
which time irreversible pulmonary lesions are already
present.
The difficulty in obtaining satisfactory amounts of
purified, standardized Asp f extract for performing reliable
and reproducible immunological tests, along with the need
for fulfilling multiple criteria, render ABPA a difficult and
complex disease to diagnose.
In order to overcome these difficulties and seeking to
simplify and standardize ABPA diagnosis, great efforts have
been invested in techniques for the production of recombi-
nant allergens.7 Some works have demonstrated that,
depending on which antibodies against these allergens are
present, one can distinguish patients with ABPA from
asthmatic patients only sensitized by the mold.8–10 Asp f
antigens belong to two functional categories: secreted
proteins and cytoplasmic proteins; allergens such as Asp f
1, Asp f 3, and Asp f 5 belonging to the first category
and Asp f 6 and, possibly, Asp f 4 and Asp f 2, to the
second. Cytoplasmic proteins are unlikely to be found in a
free form as aeroallergens, which partly explains the lack of
IgE specific for these allergens in asthmatic patients
sensitized to Asp f. By contrast, patients with ABPA show
growth of the fungus in the lungs, and its interaction with
the local cellular defense system leads to the exposure of
cytoplasmic proteins, eliciting a specific immune re-
sponse.11
Therefore, a new diagnostic tool was proposed, which
uses a panel of recombinant antigens (rAsp f) capable of
detecting only sensitization to fungus (rAsp f 1, rAsp f 3 and
rAsp f 5) or ABPA (rAsp f 2, rAsp f 4 and rAsp f 6). However,
this tool requires further evaluation before it is universally
accepted.The aims of the present study are (1) to establish early
serological diagnosis of ABPA in a group of patients
sensitized to Asp f; (2) to evaluate clinical, laboratory, and
radiological differences between asthmatic patients with
ABPA and those only sensitized; (3) to evaluate whether
serological tests for IgE specific for recombinant Asp
f allergens can aid in the detection of sensitization to this
fungus and in the diagnosis of ABPA.
Methods
An observational, cross-sectional study approved by our
Institutional Review Board was done in the outpatient
facility of Clinical Immunology and Allergy Division of
Medical School of Sa˜o Paulo University. All the patients
were informed and gave their consents. In the study 65
patients with prior diagnosis of asthma and positive
immediate-reading skin test for A. fumigatus were included,
between March 2004 and October 2005.
The percutaneous immediate-reading test was performed
by prick test, using antigenic extracts of Asp f at 5%
(Alk-Abello`s).12 If subjects did not react to the prick test,
the Asp f antigenic extract was re-administered, intrader-
mal, at 1% (Alk-Abello`s).13
Clinical history
Patients were first submitted to judicious clinical ana-
mnesis. Asthma diagnoses were confirmed and the disease
was classified into one of its severity categories, according
to the GINA criteria.14 Clinical data relevant to the study
were: age at onset of asthma, personal and family history of
the disease, use and dosage of systemic and inhaled
corticosteroids, and frequency and intensity of asthma
symptoms in the last 12 months.
Laboratory tests
On the same day as the anamnesis was performed, blood
samples were drawn for eosinophil count, measurement of
serum IgE, and serological studies. The presence of 350 cells
or more per mm3 of blood was considered as eosinophilia.15
Total IgE was measured by the UniCAPs method, using the
UniCAP 100 apparatus (Pharmacia-diagnostics), and results
were calculated in ng/ml. In addition to blood tests,
patients underwent parasitological stool tests, lung function
tests and radiological studies (thorax X-rays and high-
resolution computerized tomography (HRCT)). Lung function
tests were analyzed according to national and international
consensus criteria.16,17
Serological tests
Precipitin detection was carried out by gel diffusion.18 Three
Asp f antigens were used, two of which were purchased from
the Greer Laboratory (USA) and the other was provided by
the Clementino Fraga Filho University Hospital, RJ, Brazil.
Sera were concentrated three times by lyophilization prior
to use.19
Evaluation of serum specific IgE for A. fumigatus (IgEm3)
and for recombinant A. fumigatus antigens (rAsp f
1-IgERm218, rAsp f 2-IgERm219, rAsp f 3-IgERm220, rAsp f
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Table 1 Essential criteria in patients with ABPA
diagnosis confirmed.
Patients Total IgE
(ng/ml)
IgE m3
(kUA/l)
IgG m3
(mgA/l)
Pp Bc
Case1 6400 (+) 43.2 (+) 96.3 (+) + +
Case 2 1061 (+) 0.61 () 25.6 () + +
Case 3 2820 (+) 2.81 (+) 13 ()  +
Case 4 1380 (+) 0 () 8.42 () + +
Case 5 1608 (+) 1.36 (+) 9.05 () + +
Case 6 2520 (+) 1.25 (+) 14.8 ()  +
Pp, precipitin; Bc, bronchiectasis.
E. de Oliveira et al.23544-IgERm221 and rAsp f 6-IgERm222) were evaluated by
the UniCAPs method. Results were given in kUA/L,
where A represents allergen-specific antibodies (1 kUA/L ¼
2.4 ng/ml). Classes (0–IV) were attributed to predefined
level ranges.
Specific IgG for A. fumigatus (IgGm3) were evaluated by
the UniCAPs method. Results were given in mgA/l, where
A represents antigen-specific antibodies. For a 1:100 sample
dilution, the dosage range is 2–200mgA/l.
ABPA diagnosis
According to the essential criteria for the diagnosis of ABPA
proposed in the literature,1,2,5,6,15,20 the following findings
were valued in our group of patients: (1) positive pre-
cipitins; (2) total IgEX1000 ng/ml; (3) IgEm3Xclass II; (4)
IgGm3 above 70mg/ml and (5) central bronchiectasis. The
presence of eosinophilia in the leucogram and of pulmonary
infiltrates in the radiological tests were not considered as
essential criteria, but reinforced the diagnosis when
present.
The following diagnoses were considered: (1) certain
serological diagnosis: presence of the first four criteria; (2)
certain serological and radiological diagnosis: presence of
the second and fifth criteria along with at least one of the
other three criteria; (3) excluded diagnosis: absence of the
five criteria and (4) possible diagnosis: presence of any of
the five criteria. Due to the great difficult in making ABPA
diagnosis, we decided to use these less strict criteria.
Statistical analysis
In order to compare the differences between patients with
confirmed and excluded diagnosis of ABPA, the two-tailed
Fisher’s exact test was used. Statistical significance was
established at 5%.
Results
General characteristics
Our study sample comprised 65 patients, 40 women and 25
men, with diagnosed asthma and sensitized to Asp f as
determined by immediate-reading skin tests. Age ranged
from 12 to 81 years (mean 44.7 years; s.d. 15.83 years).
According severity classification, 72% of the patients
presented severe persistent asthma, 23% moderate persis-
tent asthma, 2% mild persistent asthma and 3% intermittent
asthma. Twelve percent patients did not use corticosteroids,
66% used only inhaled corticosteroids, and 22% used inhaled
and oral corticosteroids simultaneously. None of the patients
presented atopic dermatitis.
Sensitization to Asp f
Of the 65 patients showing reactivity to the immediate-
reading skin test, 58.46% were positive to the percutaneous
test and did not undergo to the intradermal test. The others
41.54% were negative to the percutaneous test and positive
to the intradermal test. Serum IgE specific for Asp f (IgEm3)was detected in 40% patients, with different levels of
antibodies for each patient. This antibody was detected in
47.37% percutaneous test-positive patients and in 29.63%
intradermal test-positive patients. It was equal or greater
than class II in 31.58% percutaneous test-positive patients
and in 14.81% intradermal test-positive patients.
ABPA diagnosis
Of the patients studied, 17 (26.15%) did not meet any of the
criteria for ABPA diagnosis, with the exception of positive
skin tests to Asp f. The disease was excluded in these cases.
Twenty-six patients met only one criterion, 15 met two
criteria, and a single patient met three criteria. ABPA
diagnosis could not be confirmed for any of these 42 cases
(64.60%), which correspond to the group of possible disease.
None of the patients met the criteria for serological
diagnosis (ABPA-S).
Diagnosis was confirmed in six patients who showed
central bronchiectasis and the minimal essential criteria.
Therefore, 9.20% of sensitized patients to A. fumigatus
presented ABPA. Major laboratory findings in the subgroup of
patients with confirmed ABPA diagnosis are shown (Table 1).
Comparison between patients with diagnosed ABPA
and patients sensitized to Asp f
A comparison of the clinical data of patients with (certain
diagnosed) and without (excluded) ABPA, including age,
gender distribution, age at onset of asthma, associated
atopic disease symptoms, severity of asthma, use of oral
corticosteroids, and absence from work, showed no statis-
tically significant differences between the two subgroups.
Concerning the immediate-reading skin tests for Asp f,
patients with confirmed ABPA diagnosis showed a trend
towards greater positivity to the percutaneous test, whereas
the group with excluded diagnosis showed a trend towards
greater positivity to the intradermal test.
Most patients did not show eosinophilia (66% in the
confirmed ABPA diagnosis subgroup and 53% in the excluded
diagnosis subgroup). An analysis of each of the essential
diagnostic criteria in the sample showed that 63% of patients
showed total serum IgE above 1000 ng/ml.
Sixty-six percent of ABPA patients showed a predominance of
severe obstruction, a higher prevalence than in patients without
ABPA. However, this difference was not significant.
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large airways in both subgroups was thickening of the bronchial
wall, which was present in 100% of patients with confirmed
ABPA diagnosis and in 72% of patients with excluded diagnosis.
All patients with ABPA showed central bronchiectasis. Of the
17 patients without ABPA, only one showed no alterations in
the computerized tomography. The only case of presence of
signs of fibrosis came from the ABPA subgroup. Regarding the
small airways, bronchiolar dilatation was present only in
patients with diagnosed ABPA. Centrolobular nodules were
found in 60% of patients with ABPA and in only 12% of sensitized
patients, but this difference was not significant. Central
bronchiectasis was not seen in the thorax X-rays of three
(50%) patients in the confirmed ABPA subgroup. This confirms
that chest radiographs are insensitive compared to chest CT. Of
the alterations detected by X-ray, pulmonary hyperinflation
and thickening of the bronchial walls were common findings in
both groups. Irregular nodules and opacities were found only in
patients with ABPA.
Serological tests
Only eight patients (12%) showed positive results in the
precipitin assay, four of them from the ABPA group.
Nineteen patients (29%) showed detectable levels of IgE
specific for at least one of the recombinant allergens. Analyzed
individually, IgE against rAsp f 2 and rAsp f 3 were those most
frequently found, and in some cases were the only antibodies
detected. The majority of patients with detectable levels of
IgE specific for the recombinant allergens also showed IgE
reactive to the natural antigens of Asp f (IgEm3).
Of the six patients in the diagnosed ABPA subgroup, only
two showed serum IgE specific for the recombinant allergens
(Table 2). One of the patients showed different levels (classes
I–IV) of these antibodies against the five allergens tested,
whereas one showed antibodies only against Asp f 3 (class I).
In the group of 17 patients for which ABPA was excluded,
no specific serum IgE against any of the recombinant
allergens was detected.
Discussion
Difficulties in diagnosing ABPA, as those frequently reported
in the literature, were faced at each of the stages of the
present work. An older Brazilian study had already showed
low rate of asthma and rhinitis patients with positiveTable 2 Specific IgE against recombinant allergens in patients
Serum IgE Patients
Case 1 Case 2
IgERm 218 (r Asp f 1) D (11.1) U
IgERm 219 (r Asp f 2) D (22.9) U
IgERm 220 (r Asp f 3) D (15.1) D (0.53)
IgERm 221 (r Asp f 4) D (0.42) U
IgERm 222 (r Asp f 6) D (7.73) U
D, detectable; U, undetectable.
Serum level—kU/l.percutaneous test to Asp f (4.44%).21 When analyzing patient
sensitization, there were great discrepancies between skin
test results and the presence of serum IgE specific for Asp f
(IgEm3); of the 65 patients with positive percutaneous or
intradermal tests, only 26 (40%) also had detectable IgEm3.
Most intradermal test-positive patients had IgEm3 less than
class II (85.19%). Similar discrepancies have also been
reported in the literature.4 Some factors must be consid-
ered, such as 1) the use of extracts from different sources
for in vivo and in vitro tests; 2) the use of fungal extracts
that are not yet standardized; 3) false positive skin tests,
mainly the intradermal test; 4) the patients may be
sensitized to an Asp f allergen other than those tested; 5)
the patients may be sensitized to a fungal which shows
cross-reactivity to Asp f; 6) low titers of circulating IgE
against the allergenic components, which are present in low
concentrations in the allergenic extract. This last reason
could be due to a strong suppression of the IgE immune
response by corticoteroids.
ABPA diagnosis was excluded in 17 (26%) and confirmed in
six (9.20%) of the patients sensitized to Asp f. Even in these
six patients, ABPA diagnosis could be questionable, because
we used less strict criteria. Studies of the prevalence of this
disease among A. fumigatus sensitized asthmatic patients
show results that range from 6% to 28%,4,15,22 which may be
due to the lack of a single test to establish ABPA diagnosis.
There were no statistically significant differences with
respect to clinical, laboratory, or radiological findings
between patients with confirmed ABPA and those with
excluded diagnosis, probably due to the small number of
patients in the confirmed diagnosis subgroup. Asthma was
severe in all patients with ABPA and in 76% of patients
without the disease.
A purely serological diagnosis (ABPA-S) was not able to be
established. The six patients diagnosed with ABPA showed
central bronchiectasis. Only one of these patients fulfilled
all serological criteria, another patient fulfilled 3 of the
criteria and the other four patients fulfilled two criteria.
Diagnosis could not be confirmed but remained suspected
in 42 patients (64.60%), with greater probability in three
patients showing central bronchiectasis alone, in two
patients with bronchiectasis associated with one of the
serological criteria, and in a single patient who fulfilled
three serological criteria but showed none of the radio-
logical criteria.
There is a well-known advantage of the early diagnosis
and adequate treatment of ABPA to the clinical evolution ofwith ABPA diagnosis confirmed.
Case 3 Case 4 Case 5 Case 6
U U U U
U U U U
U U U U
U U U U
U U U U
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irreversible pulmonary lesions.23 The fact that no serological
diagnosis could be made in the present study, and the large
number of patients whose diagnoses remained uncertain
reflects the difficulties in establishing an ABPA diagnosis.
The analysis of the levels of Asp f-specific IgE (IgEm3) and
IgG (IgGm3), serological criteria specific for Asp f, showed
that 16 patients (25%) showed IgEm3X class II, and only two
patients (3%) showed IgGm3X70mgA/l. Generally speaking,
these levels are low when compared to the results found by
other groups.10,22
In the subgroup of patients diagnosed with ABPA, four out
of six patients tested positive for precipitins. Positivity to
this test among patients with ABPA ranges from 57.10% to
100% in different works in the literature.5,15,24 Precipitins
not specific for ABPA were present in approximately 10% of
patients with asthma and without ABPA.1 Gel immunodiffu-
sion showed greater positivity when compared to the IgGm3
assay, perhaps due to the greater number of extracts used.
The only two patients with IgGm3X70mgA/l also showed
precipitins; one of these patients was from the ABPA
subgroup.
The majority of patients with ABPA did not show
eosinophilia. As is the case with serological exams,
eosinophilia may be negative in periods of disease remission
and during corticosteroid use. ABPA was confirmed in one of
the 14 patients in the sample under continuous treatment
with inhaled and oral corticosteroids. The majority of
patients (64.30%) were placed in the suspected diagnosis
group.
The presence of central bronchiectasis established by
HRCT, one of the essential diagnostic criteria established,
was observed in 11 patients (17%) in the sample, of which six
were confirmed as having ABPA.
The individual analysis of each specific serum IgE (IgER) in
the group of 65 patients showed that IgE anti-rAsp f 2 and
anti-rAsp f 3 were detected in a greater number of patients,
with a frequency of 8% and 26%, respectively. There are no
studies comparing the positivity of skin tests performed with
a natural extracts of Asp f and the levels of serum IgE
specific for recombinant allergens derived from this fungus.
The repeated analysis of each IgER in the group of 26
patients that, in addition to positive skin tests, also showed
detectable levels of IgEm3, showed an increased positivity.
IgE anti-rAsp f 2 was present in 19% of patients and IgE anti-
rAsp f 3 was in 54%, maintaining their position as the most
reactive antigens, whereas IgE anti-rAsp f 1 was detectable
in only 12% of patients. IgE anti-rAsp f 2 and anti-rAsp f 3
were the only antibodies to appear alone. None of the 17
patients in the excluded diagnosis subgroup showed detect-
able IgER levels. The levels of specific serum IgE against
recombinant allergens were below those described in the
literature, and rAsp f 1 did not behave as a major allergen.11
In the subgroup of patients with ABPA, only one patient
showed detectable levels of IgE against all recombinant
allergens, while another patient showed only IgE against
rAsp f 3.
In the literature there is some evidence that recombinant
Asp f allergens can be useful for elucidating the diagnosis of
ABPA in cystic fibrosis patients, through their utilization in
serum IgE detection25 or intracutaneous test.26 However,
the data are not uniform and further studies with largernumbers of patients remain necessary.27–30 The evidence for
the utility of these recombinant allergens in the diagnosis of
ABPA in patients with asthma is scant.9,10
In the present study, the investigation of IgE specific for
the recombinant allergens, that could constitute a tool for
both the detection of sensitization to Asp f and for the
diagnosis of ABPA, showed no advantage over the use of
natural Asp f antigens. The lack of standardization of the
allergens used in the diagnosis of ABPA, which affects the
reproducibility of results, could not be overcome by using
the recombinant allergens used in the present study. Asp f
allergens, able to improve the detection of ABPA disease,
making diagnosis more uniform across different healthcare
facilities, remains a challenge.Conflict of interest statement
We do not have conflict of interest.References
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